Pa­tient death mars lat­est cut of da­ta from Al­lo­gene's off-the-shelf CAR-T

Al­lo­gene has been rid­ing high since AS­CO in May, when ear­ly da­ta showed their off-the-shelf CAR-T worked in a hand­ful of pa­tients and that no one re­ject­ed their for­eign cells. It was a key mo­ment in a field that could re­make cell ther­a­py and treat­ment for cer­tain can­cers.

On Wednes­day, though, the Arie Bellde­grun-found­ed biotech re­leased re­sults for their mul­ti­ple myelo­ma CAR-T and, al­though the re­spons­es were there, so was a red flag: Four pa­tients con­tract­ed a se­ri­ous in­fec­tion, and one of them died.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER